B Group Inc. Invests $399,000 in BioNTech SE (NASDAQ:BNTX)

B Group Inc. purchased a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, Holdings Channel reports. The firm purchased 3,500 shares of the company’s stock, valued at approximately $399,000. BioNTech makes up 0.2% of B Group Inc.’s portfolio, making the stock its 16th largest position.

A number of other large investors have also made changes to their positions in BNTX. FMR LLC lifted its holdings in BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company’s stock worth $877,583,000 after acquiring an additional 1,401,547 shares in the last quarter. Capital International Investors raised its position in shares of BioNTech by 38.6% during the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock worth $161,304,000 after purchasing an additional 394,434 shares during the period. abrdn plc lifted its holdings in shares of BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock valued at $43,947,000 after purchasing an additional 159,676 shares in the last quarter. Franklin Resources Inc. grew its position in shares of BioNTech by 3,942.1% in the 4th quarter. Franklin Resources Inc. now owns 136,786 shares of the company’s stock valued at $15,587,000 after purchasing an additional 133,402 shares during the period. Finally, CenterBook Partners LP increased its stake in BioNTech by 62.5% during the 4th quarter. CenterBook Partners LP now owns 194,118 shares of the company’s stock worth $22,120,000 after purchasing an additional 74,656 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on BNTX shares. Citigroup started coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target on the stock. Truist Financial started coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. BMO Capital Markets lifted their price target on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Morgan Stanley decreased their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Stock Performance

NASDAQ BNTX opened at $98.76 on Monday. The firm has a market capitalization of $23.70 billion, a P/E ratio of -47.03 and a beta of 1.07. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $102.79 and its two-hundred day moving average price is $110.94. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the prior year, the firm earned $1.90 EPS. BioNTech’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, research analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.